EMA Authorised: Emgality (Galcanezumab) — Eli Lilly Nederland B.V.

View source ↗

Summary

The European Medicines Agency authorised Emgality (galcanezumab) for migraine disorders, with Eli Lilly Nederland B.V. listed as the marketing authorisation hol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• Emgality (galcanezumab)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: Eli Lilly Nederland B.V.. Decision date: 27/01/2026